Stada loses EUR 14.3 million in final quarter of 2016 – Company expects profit of around EUR 200 million in 2017

The German pharmaceutical company Stada Arzneimittel has reported a loss from the final quarter of 2016, whereas the management has confirmed the expectations for the current year, as well as the strategic outcome for 2019, previously reviewed up on March 17.

The net loss in the fourth quarter amounted to EUR 14.3 million, that is, EUR 0.23 per share, compared to the net profit of EUR 20.5 million (EUR 0.33 per share) in the corresponding period of 2015. EBITDA dropped from EUR 95.9 million to EUR 72.4 million, whereas adjusted profit per share dropped from EUR 0.62 to EUR 0.60.

The sales in the October-December period rose by 2.7% to EUR 597.5 million, Wisebroker reports.

The management expects sales between EUR 2.28 and 2.35 billion in the current year, adjusted for currency effects, adjusted EBITDA between EUR 430 and 450 million and adjusted net profit of EUR 195 and 205 million.

According to the revised plans for 2019, the company expect sales of EUR 2.65 to 2.70 billion, adjusted EBITDA of EUR 570 to 590 million and adjusted net profit of EUR 250 to 270 million.

Stada is undergoing a process of sale, but the management has estimated offers by investment funds at the price of EUR 58 per share, bringing the company's value to EUR 3.6 billion, to be insufficient. Nevertheless, negotiations with potential buyers have continued. Stada's shares rose slightly to EUR 57.2 yesterday.

STADA Grupa

Stada Arzneimittel Germany

medical drug manufacture

Stada loss

Stada profit

Stada revenues

Stada EBITDA